ASCLETIS-B News

Goli Pharmaceutical-B (1672.HK) 2023 Annual Results Announcement Comment: Losses narrowed sharply year over year, focus on multi-milestone events catalyzed

東北證券Apr 8 00:00

Goli Pharmaceutical-B (01672.HK): 23 years of steady growth, focusing on differentiated innovation pipelines, deepening R&D in the MASH field

方正證券Mar 27 00:00

Goli Pharmaceutical-B (1672.HK): Innovative drug development has achieved excellent results and sufficient cash reserves

國元國際Mar 26 00:00

Goli Pharmaceutical (1672.HK) Announcement Comment: ASC41 Announces Phase 2 Interim Data?? Possesses BEST-IN-CLASS potential for the same target

光大證券Jan 8 13:32

Geli Pharmaceutical-B (1672.HK): Excellent clinical data on ASC40 treatment of acne stage II, broad market space

國元國際May 3, 2023 00:00

Geli Pharmaceutical-B (1672.HK): Promoting new drug research and development smoothly and actively exploring international cooperation

國元國際Mar 20, 2023 00:00

Geli Pharmaceutical-B (1672.HK): Good results in phase II clinical trials of a new drug for fatty liver disease, further on the road to innovation

平安證券Jun 18, 2020 00:00

Geli Pharmaceutical (1672.HK): Sales growth is good, focusing on clinically developed varieties

平安證券Mar 25, 2020 00:00

Garei Pharmaceutical-B (1672.HK): An Innovative Antiviral Drug Company: Light for Liver Disease Patients

平安證券Feb 15, 2020 00:00

Geli Pharmaceutical-B (01672.HK): Downgraded to target price of HK$3.7 at the same time as the market

摩根士丹利Jan 6, 2020 00:00